Regulatory issues in female sexual dysfunction.
Female sexual dysfunction (FSD) remains an enigmatic area to some, a controversial area to others and the subject of continued, intense debate in the literature. Questions remain regarding the legitimacy of FSD as a bona fide disease; the definition of FSD; the methods of diagnosis; and, the treatment of FSD. In this timely perspective, Jean Fourcroy, Consultant in Urology, Endocrinology and Regulatory Issues, discusses the controversies that continue to plague FSD.
Fourcroy
J L
JL
U.SU.H.S./Walter Reed Army Hospital, Bethesda, MD 20817, USA. sjlfbehr@aol.com
D002986:Clinical Trials as Topic / Q000592:standards; D005260:Female; D006801:Humans; D012735:Sexual Dysfunction, Physiological / Q000175:diagnosis* / Q000503:physiopathology / Q000628:therapy; D020018:Sexual Dysfunctions, Psychological / Q000175:diagnosis* / Q000503:physiopathology / Q000628:therapy; D014481:United States; D014486:United States Food and Drug Administration